Company intelligence / Profile preview

Nu Eyne

Seoul, Seoul, South Koreadnb.com ↗

Ownership: Private
Development stage: Commercial

Overview

ELEXIR has demonstrated efficacy as a noninvasive acute/preventive migraine relief device; ongoing pivotal trials are evaluating its use in dry eye syndrome post-LASEK surgery. The company is also advancing preclinical/early clinical programs for tissue regeneration and anticancer effects using bioelectronic stimulation modalities.

Therapeutic areas: PsychiatryUrologyOphthalmologyOncologyNeurology
Modalities: DeviceNon-pharmacological therapyBioelectronic medicine
Industry: Biotech

Drug pipeline

2 assets

ADDNOX

Commercial

Indications: ADHD

1 more asset in the full pipeline.

Request access →

Partnerships

Dong-A PharmaceuticalSamsung Medical CenterJohnson & Johnson

Beyond the preview

Go deeper on Nu Eyne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nu Eyne.

Explore the full profile